

MediWound Snapshot (Nasdaq: MDWD)

Validated breakthrough platform technology with commercial product – NexoBrid®, and promising late-stage product candidate – EscharEx®

Strategic U.S. partnerships and solid balance sheet supporting development activities

Upcoming meaningful milestones in both programs

EscharEx: Potential game changer with a substantial market opportunity in a sizeable market

- U.S. Phase 2 adaptive design study for treatment of venous leg ulcers is up and running, with an interim assessment anticipated in 1H/2021
- Study is designed to assess the efficacy and safety of EscharEx compared to gel vehicle (placebo control), as well as head-to-head with the current non-surgical standard of care in the U.S.
- Significant market opportunity in chronic wound debridement with targeted addressable market of over \$2 billion in U.S. alone with current enzymatic debridement agent generates more than \$300 million every year
- Broader enzymatic use with a clear unmet need for rapid and effective enzymatic agent

NexoBrid: Commercial product with Strategic U.S. partnerships with BARDA and Vericel accompanied by global expansion

- Positive U.S. Phase 3 top-line results for NexoBrid
- BLA filing planned for mid-2020, and expect for a PDUFA date around midyear 2021
- NexoBrid expanded access program is up and running to treat burn patients during the ongoing preparation and review of the BLA

- Commercial collaboration with Vericel in North America provides near-term cash inflows including milestone payments, royalty payments and manufacturing price
- Substantial support by BARDA: R&D programs are fully funded and procurement for emergency stockpile valued at \$16.5 million was initiated
- Continues global expansion of NexoBrid through new distribution agreement

Solid balance sheet to fund ongoing EscharEx Development

- Cash of \$27.3 million as of 3/31/2020 and no debt
- Generated revenues of \$32 million in 2019, including upfront payment of \$17.5 million from Vericel collaboration; 1Q 20 revenues of \$4.4 million
- NexoBrid is cash flow positive and continues to support our balance sheet
- Cash on hand and expected cash inflows from NexoBrid, support EscharEx development plan

Upcoming meaningful milestones

- ▶ Submission of NexoBrid BLA in mid-year 2020
- ▶ EscharEx interim analysis in 1H/2021